Results 1 to 10 of about 148,083 (310)

Change in Eosinophil Count in Patients with Heart Failure Treated with Anakinra

Cells, 2023
Background: Interleukin-1 blockade with anakinra leads to a transient increase in eosinophil blood count (eosinophils) in patients with acute myocardial infarction. We aimed to investigate the effect of anakinra on changes in eosinophils in patients with
Michele Golino, Francesco Moroni, Marco Giuseppe Del Buono, Justin M. Canada, Azita H. Talasaz, Sebastian Piñel, James Mbualungu, Alessandra Vecchiè, Ai-Chen (Jane) Ho, Georgia K. Thomas, Salvatore Carbone, Hayley E. Billingsley, Jeremy Turlington, Roshanak Markley, Cory Trankle, Roberto De Ponti, Benjamin Van Tassell, Antonio Abbate   +17 more
doaj   +1 more source

Anakinra to Mitigate Hemophagocytic Lymphohistiocytosis-Like Toxicity Following Chimeric Antigen Receptor T-cell Therapy in Pediatric B-cell ALL

Clinical Pediatric Hematology-Oncology, 2022
Hemophagocytic lymphohistiocytosis-like toxicity following chimeric antigen receptor (CAR)-T cell therapy (carHLH) is a rare and fulminant complication.
Na Yoon Lee, Suejung Jo, Jae Won Yoo, Seongkoo Kim, Jae Wook Lee, Nack-Gyun Chung, Bin Cho   +6 more
doaj   +1 more source

An interleukin-1 receptor antagonist protein protects insulin-producing Beta cells against suppressive effects of interleukin-1? [PDF]

Diabetologia, 1991
The cytokine interleukin-1 beta may have an important role in the autoimmune mediated damage of pancreatic Beta cells in insulin-dependent diabetes mellitus. In the present study we have investigated the effects of an interleukin-1 receptor antagonist protein, a blocker of the type I interleukin-1 receptor, on the suppressive actions of recombinant ...
Eizirik, Decio L., Tracey, D E, Bendtzen, K, Sandler, S   +3 more
openaire   +2 more sources

A new treatment for hip osteoarthritis: clinical evidence for the efficacy of autologous conditioned serum

Orthopedic Reviews, 2013
The purpose of the present study was to investigate the effect of intra-articular injections of autologous conditioned serum on human hip osteoarthritis and to test whether a potential treatment effect might be increased by additional injections of ...
Axel W.A. Baltzer, Martin S. Ostapczuk, Daniel Stosch, Florian Seidel, Markus Granrath   +4 more
doaj   +1 more source

Cloning and Expression of Recombinant Human Interleukin 1 Receptor Antagonist in Escherichia Coli Strains, BL21 (DE3), Rosetta (DE3), and Origami (DE3)

مجله دانشکده پزشکی اصفهان, 2019
Background: Recombinant human interleukin-1 receptor antagonist (IL-1RA) is a protein with 153 amino acids and molecular weight of 16.83 kDa. This drug protein is known as Anakinra, and has an effective application in the treatment of rheumatoid ...
Hanieh Fardgoli, Seyed Nezameddin Hoseini, Setareh Haghighat   +2 more
doaj   +1 more source

Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. [PDF]

Journal of Clinical Investigation, 1997
Interleukin 1 receptor antagonist (IL-1Ra) levels are elevated in the blood of patients with a variety of infectious, immune, or traumatic conditions. To examine whether IL1Ra is produced by liver cells with characteristics resembling an acute-phase protein, human primary hepatocytes isolated from liver biopsies and HepG2 hepatoma cells were stimulated
C, Gabay, M F, Smith, D, Eidlen, W P, Arend   +3 more
openaire   +2 more sources

Biologic effects of an interleukin‐1 receptor antagonist protein on interleukin‐1–stimulated cartilage erosion and chondrocyte responsiveness [PDF]

Arthritis & Rheumatism, 1991
AbstractRecombinant human interleukin‐1α (IL‐1α) and recombinant human IL‐1β stimulate matrix proteoglycan degradation and inhibit glycosaminoglycan synthesis in bovine nasal cartilage explants. A 17‐kd human recombinant IL‐1 receptor antagonist protein (IRAP) caused a concentration‐dependent (0.2–200 ng/ml) suppression of the effects of IL‐1α and IL ...
R J, Smith, J E, Chin, L M, Sam, J M, Justen   +3 more
openaire   +2 more sources

A novel mutation of interleukin-1 receptor antagonist (IL1RN) in a DIRA patient from Turkey: Diagnosis and treatment

The Turkish Journal of Pediatrics, 2018
Autoinflammatory diseases can cause severe inflammation in bone and skin such as neonatal-onset multisystem inflammatory disease (NOMID), Majeed syndrome, interleukin-36 receptor antagonist deficiency (DITRA) and deficiency of interleukin-1 (IL-1 ...
Betül Sözeri, Bengü Gerçeker-Türk, Başak Yıldız-Atıkan, Sevgi Mir, Afig Berdeli   +4 more
doaj   +1 more source

The interleukin-1 receptor antagonist influences interleukin-1 effects in rat and mouse

Mediators of Inflammation, 1992
In this work we have focused on the ability of interleukin-1 to induce an acute phase protein response and a degranulation of polymorphonuclear leukocytes in vivo.
P. Bjrök, K. Ohlsson
doaj   +1 more source

Evaluation of serum interleukin‐1 receptor antagonist levels in major depressive disorder: A case‐control study

Health Science Reports, 2023
Background and Aims Major depressive disorder (MDD) is characterized by the occurrence of one or more depressive episodes lasting a minimum of 2 weeks and is marked by a persistently low mood and a lack of enjoyment in daily activities.
Zabun Nahar, Shahrin Tasnim Monisha, MMA Shalahuddin Qusar, Md. Rabiul Islam   +3 more
doaj   +1 more source